Table 2 Schedule of study assessments

 Eligibility screen

X

 Informed consent

X

 Randomization

X

Intervention

 30s-CST (primary outcome)

X

X

X

X

 6MWT

X

X

X

X

 Handgrip strength

X

X

X

X

 Gait speed test

X

X

X

X

 Physical activity^a

X

X

 DXA

X

X

 BI

X

X

 Body weight^a

X

X

X

X

 Inflammatory biomarkers

X

X

X

X

 PRPS

X

X

X

X

 MDASI^a

X

X

X

X

 EORTC-QLQ-C30

X

X

X

X

 HADS

X

X

X

X

Qualitative exploration

 Individual Interviews

X

 Adherence

X

X

X

X

X

X

X

X

X

X

X

X

X

X

 Attrition

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

 Adverse events

X

X

X

X

X

X

X

X

X

X

X

X

X

X

 Treatment related toxicity^b

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

 Dose-reductions^b

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Hospitalizations

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Survival

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X